Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis
Ayalew Tefferi, Animesh Pardanani, Naseema Gangat
Haematologica (2023) Vol. 108, Iss. 11, pp. 2919-2932
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
Robert Roskoski
Pharmacological Research (2024) Vol. 200, pp. 107059-107059
Open Access | Times Cited: 146
Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management
Ayalew Tefferi, Tiziano Barbui
American Journal of Hematology (2023) Vol. 98, Iss. 9, pp. 1465-1487
Open Access | Times Cited: 72
Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices
Ayalew Tefferi, Animesh Pardanani, Naseema Gangat
American Journal of Hematology (2024) Vol. 99, Iss. 2, pp. 300-308
Closed Access | Times Cited: 9
Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
Ayalew Tefferi, Animesh Pardanani
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects
Yi‐Ru Bai, Dong‐Jie Seng, Ying Xu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116706-116706
Closed Access | Times Cited: 6
Nitrogen-Containing Heterocyclic Drug Products Approved by the FDA in 2023: Synthesis and biological activity
Weijiang Luo, Yiqi Liu, Hui Qin, et al.
European Journal of Medicinal Chemistry (2024) Vol. 279, pp. 116838-116838
Closed Access | Times Cited: 6
Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements
Tanvi Verma, Nikolaos Papadantonakis, Deniz Peker Barclift, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 514-514
Open Access | Times Cited: 5
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single‐arm, open‐label, phase 2, multicenter study
Yi Zhang, Hu Zhou, Minghui Duan, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 10, pp. 1588-1597
Open Access | Times Cited: 14
Anemia in patients receiving anticancer treatments: focus on novel therapeutic approaches
Claudia Bozzini, Fabiana Busti, Giacomo Marchi, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Clinical assessment of momelotinib drug–drug interactions via CYP3A metabolism and transporters
Y. Ho, Peter D. Gorycki, Geraldine Ferron‐Brady, et al.
Clinical and Translational Science (2024) Vol. 17, Iss. 4
Open Access | Times Cited: 4
Identification of therapeutic target genes for age-related hearing loss through systematic genome-wide mendelian randomization of druggable genes
Kun Zhang, Bo Hou, Tao Yan, et al.
Experimental Gerontology (2025) Vol. 200, pp. 112676-112676
Open Access
Cytopenias and Large Splenomegaly are Main Drivers of Poor Outcome after Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis
Francesca Palandri, Massimo Breccia, Erika Morsia, et al.
(2025)
Closed Access
Helicobacter pylori infection induces DNA double-strand breaks through the ACVR1/IRF3/POLD1 signaling axis to drive gastric tumorigenesis
Xinbo Xu, Fei Xiao, Huan Wang, et al.
Gut Microbes (2025) Vol. 17, Iss. 1
Open Access
Disease phenotype significantly influences the outcome after discontinuation of ruxolitinib in chronic phase myelofibrosis.
Francesca Palandri, Massimo Breccia, Erika Morsia, et al.
Clinical Lymphoma Myeloma & Leukemia (2025)
Open Access
Emerging Pathogenetic Mechanisms and New Drugs for Anemia in Myelofibrosis and Myelodysplastic Syndromes
Naseema Gangat, Ayalew Tefferi
American Journal of Hematology (2025)
Closed Access
Pharmacological aspects of FDA-approved novel drug therapies against cancer in 2023: a comprehensive review
Kavita Sangwan, Parveen Kumar Goyal, Vipasha Sharma
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Analysis of network expression and immune infiltration of disulfidptosis‐related genes in chronic obstructive pulmonary disease
Liu Yan-qun, Tao Zhu, Juan Wang, et al.
Immunity Inflammation and Disease (2024) Vol. 12, Iss. 4
Open Access | Times Cited: 3
New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors
Naseema Gangat, Ayalew Tefferi
American Journal of Hematology (2024) Vol. 99, Iss. 5, pp. 978-981
Closed Access | Times Cited: 2
Efficacy, safety, and survival findings after long‐term follow‐up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis
Yi Zhang, Hu Zhou, Zhongxing Jiang, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 774-779
Open Access | Times Cited: 2
Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant
Ayalew Tefferi, Animesh Pardanani, Kebede H. Begna, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
miR‐146a−/− mice model reveals that NF‐κB inhibition reverts inflammation‐driven myelofibrosis‐like phenotype
Ernesto José Cuenca‐Zamora, Pedro Jesús Guijarro-Carrillo, María José López-Poveda, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 7, pp. 1326-1337
Closed Access | Times Cited: 2
Safety and efficacy of jaktinib (a novelJAKinhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: Asingle‐arm,open‐label, phase 2, multicenter study
Yi Zhang, Qike Zhang, Qingchi Liu, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 10, pp. 1579-1587
Open Access | Times Cited: 6
Clinical pharmacokinetic characteristics of Jaktinib in subjects with hepatic impairment in a phase I trial
Man-Na Zhao, Hua Zhang, Sheng Ma, et al.
Drug Metabolism and Pharmacokinetics (2024) Vol. 59, pp. 101030-101030
Closed Access | Times Cited: 1
Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations
Harinder Gill, Garret M. K. Leung, Yok-Lam Kwong
Hematology (2023) Vol. 2023, Iss. 1, pp. 667-675
Closed Access | Times Cited: 3
Jaktinib and momelotinib for the treatment of myelofibrosis—Birds of a feather?
Ayalew Tefferi
American Journal of Hematology (2023) Vol. 98, Iss. 10, pp. 1517-1519
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top